Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botensilimab + Balstilimab vs Best Supportive Care in Chemo-refractory Colorectal Cancer
NCT07152821Phase 3Terminated
- Sponsor
- Canadian Cancer Trials Group
- Start
- Mar 2026
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in colorectal cancer (CRC) comparing Best Supportive Care with Botensilimab + Balstilimab and Best Supportive Care (2 arms). Primary endpoint: Overall Survival at 34 months. Started Mar 2026; status: terminated.
02
Drugs
botensilimabbalstilimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07152821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07152821.